{"subsection_name": "Dealbook", "pub_date": "2011-10-03T09:20:01Z", "byline": {"original": "By PETER LATTMAN", "person": [{"lastname": "LATTMAN", "organization": "", "rank": 1, "role": "reported", "firstname": "Peter"}]}, "abstract": "The Carlyle Group and Hellman & Friedman agreed to buy Pharmaceutical Product Development in one of the largest private equity deals this year.", "word_count": "507", "print_page": null, "news_desk": null, "snippet": "The Carlyle Group and Hellman & Friedman agreed to buy Pharmaceutical Product Development in one of the largest private equity deals this year.", "multimedia": [{"subtype": "thumbnail", "width": 75, "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2011/10/03/business/dbpix-people-rubenstein-hellman/dbpix-people-rubenstein-hellman-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "url": "images/2011/10/03/business/dbpix-people-rubenstein-hellman/dbpix-people-rubenstein-hellman-thumbStandard.jpg", "height": 75}], "source": "The New York Times", "blog": [], "keywords": [], "type_of_material": "Blog", "lead_paragraph": null, "web_url": "http://dealbook.nytimes.com/2011/10/03/carlyle-and-hellman-friedman-to-buy-ppd-for-3-9-billion/", "section_name": "Business Day", "headline": {"main": "Buyout Firms to Buy Drug Research Company for $3.9 Billion", "print_headline": "Buyout Firms To Acquire Drug Concern", "kicker": "DealBook"}, "slideshow_credits": null, "_id": "54f3db4738f0d84018917fdc", "document_type": "blogpost"}